IFNA1 and myeloid sarcoma: We validated the ability of identified potential biomarkers and their cut-offs to predict CSP on an independent group of patients treated with IFN, i.e., with a drug with a different mechanism of action against GA, in order to assess the robustness of these cut-offs (general utilization for patients with MS independent of their treatment).